Show simple item record

dc.contributor.authorSabaté, Mònica
dc.contributor.authorFerrer, Pili
dc.contributor.authorBallarín, Elena
dc.contributor.authorRottenkolber, Marietta
dc.contributor.authorAmelio, Justyne
dc.contributor.authorSchmiedl, Sven
dc.contributor.authorReynolds, Robert
dc.contributor.authorKlungel, Olaf
dc.contributor.authorIbáñez, Luisa
dc.date.accessioned2016-04-14T11:48:15Zen
dc.date.available2016-04-14T11:48:15Zen
dc.date.issued2015-03en
dc.date.submitted2016en
dc.identifier.citationBasic Clin. Pharmacol. Toxicol. 2015, 116 (3):201-11 Basic Clin. Pharmacol. Toxicol.en
dc.identifier.issn1742-7843en
dc.identifier.pmid25420967en
dc.identifier.doi10.1111/bcpt.12358en
dc.identifier.urihttp://hdl.handle.net/2336/605250en
dc.descriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the pageen
dc.description.abstractDrug utilization (DU) studies in inpatient settings at a national level are rarely conducted. The main objective of this study was to review the general information on hospital medicine management in Europe and to report on the availability and characteristics of nationwide administrative drug consumption databases. A secondary objective was to perform a review of published studies on hospital DU of a group of selected drugs, focusing on methodological characteristics (ATC/DDD). General information on hospital drug management was retrieved from several websites, nationwide administrative drug consumption databases and reports published by governmental organizations. A PubMed search was conducted using keywords related to the selected group of drugs AND 'hospital drug utilization'. The data sources for hospital DU information varied widely and included 14 databases from 25 reviewed countries. Bulgaria, Croatia, Denmark, Estonia, Finland, France, Hungary, Iceland, Latvia, Norway and Sweden obtain information on inpatient DU at a national level from wholesalers/manufacturers. In Belgium, Italy and Portugal, drugs dispensed to patients in hospitals are registered at a national level. Data are freely available online only for Denmark and Iceland. From the PubMed search, of a total of 868 retrieved studies, only 13 studies used the ATC/DDD methodology. Although the number of DDD/100 bed-days was used in four studies, other units of measure were also used. The type of information provided for the inpatient sector allowed primarily for conducting DU research at an aggregated data level. The existence of national administrative structures to monitor hospital DU would contribute to promoting the rational use of medicines and improving the safety and quality of prescribing.
dc.description.sponsorshipInnovative Medicines Initiative Joint Undertaking 115004 info:eu-repo/grantAgreement/EC/FP7/115004en
dc.description.sponsorshipinfo:eu-repo/grantAgreement/EC/FP7/115004en
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.relation.urlhttp://dx.doi.org/ 10.1111/bcpt.12358en
dc.relation.urlhttp://onlinelibrary.wiley.com/doi/10.1111/bcpt.12358/epdfen
dc.rightsArchived with thanks to Basic & clinical pharmacology & toxicologyen
dc.subjectLyfjanotkunen
dc.subjectSjúkrahúsen
dc.subject.meshDatabases, Factualen
dc.subject.meshDrug Utilizationen
dc.subject.meshEuropeen
dc.subject.meshHospitalsen
dc.subject.meshHumansen
dc.subject.meshInpatientsen
dc.subject.meshPractice Patterns, Physicians'en
dc.titleInpatient drug utilization in Europe: nationwide data sources and a review of publications on a selected group of medicines (PROTECT project).en
dc.typeArticleen
dc.contributor.departmentAddresses: [ 1 ] Fundacio Inst Catala Farmacol, Barcelona, Spain [ 2 ] Univ Hosp Vall dHebron, Dept Clin Pharmacol, Barcelona, Spain [Show the Organization-Enhanced name(s)] [ 3 ] Autonomous Univ Barcelona, Hosp Univ Vall dHebron, Dept Pharmacol Toxicol & Clin Therapeut, Barcelona 08029, Spain [Show the Organization-Enhanced name(s)] [ 4 ] Univ Munich, Inst Med Informat Sci Biometry & Epidemiol, Munich, Germany [ 5 ] Amgen Inc, Uxbridge, Middx, England [ 6 ] Helios Klin Wuppertal, Philipp Klee Inst Clin Pharmacol, Wuppertal, Germany [Show the Organization-Enhanced name(s)] [ 7 ] Univ Witten Herdecke, Fac Hlth, Sch Med, Dept Clin Pharmacol, Witten, Germany [Show the Organization-Enhanced name(s)] [ 8 ] Pfizer Res & Dev, Epidemiol, New York, NY USA [Show the Organization-Enhanced name(s)] [ 9 ] Univ Utrecht, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlandsen
dc.identifier.journalBasic & clinical pharmacology & toxicologyen
dc.rights.accessNational Consortium - Landsaðganguren
html.description.abstractDrug utilization (DU) studies in inpatient settings at a national level are rarely conducted. The main objective of this study was to review the general information on hospital medicine management in Europe and to report on the availability and characteristics of nationwide administrative drug consumption databases. A secondary objective was to perform a review of published studies on hospital DU of a group of selected drugs, focusing on methodological characteristics (ATC/DDD). General information on hospital drug management was retrieved from several websites, nationwide administrative drug consumption databases and reports published by governmental organizations. A PubMed search was conducted using keywords related to the selected group of drugs AND 'hospital drug utilization'. The data sources for hospital DU information varied widely and included 14 databases from 25 reviewed countries. Bulgaria, Croatia, Denmark, Estonia, Finland, France, Hungary, Iceland, Latvia, Norway and Sweden obtain information on inpatient DU at a national level from wholesalers/manufacturers. In Belgium, Italy and Portugal, drugs dispensed to patients in hospitals are registered at a national level. Data are freely available online only for Denmark and Iceland. From the PubMed search, of a total of 868 retrieved studies, only 13 studies used the ATC/DDD methodology. Although the number of DDD/100 bed-days was used in four studies, other units of measure were also used. The type of information provided for the inpatient sector allowed primarily for conducting DU research at an aggregated data level. The existence of national administrative structures to monitor hospital DU would contribute to promoting the rational use of medicines and improving the safety and quality of prescribing.


This item appears in the following Collection(s)

Show simple item record